Treating ALK-positive lung cancer—early successes and future challenges

Camidge, D. Ross; Doebele, Robert C.

doi:10.1038/nrclinonc.2012.43

Cited by 236Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment

Treating ALK-positive lung cancer—early successes and future challenges

Open access

Camidge, D. Ross, Doebele, Robert C.·2012·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2012.43PMC PMC4142046

Open this paper in CoChat — free account

Abstract

Rearrangements of the anaplastic lymphoma kinase (ALK) gene occur infrequently in non-small-cell lung cancer (NSCLC), but provide an important paradigm for oncogene-directed therapy in this disease. Crizotinib, an orally bioavailable inhibitor of ALK, provides significant benefit for patients with ALK-positive (ALK+) NSCLC in association with characteristic, mostly mild, toxic effects, and this drug has been approved by the FDA for clinical use in this molecularly defined subgroup of lung cancer. Many new ALK inhibitors are being developed and understanding the challenges of determining and addressing the adverse effects that are likely to be ALK specific, while maximizing the time of benefit on targeted agents, and understanding the mechanisms that underlie drug resistance will be critical in the future for informing the optimal therapy of ALK+ NSCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2012.43

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

ALK gene rearrangements are identified in a small proportion of newly diagnosed patients with NSCLC (approximately 5%).
“ALK gene rearrangements are identified in a small proportion of newly diagnosed patients with NSCLC (approximately 5%).77,87–89”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [88]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · see citing works
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,442 · see citing works
Self-citation
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · see citing works
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,404 · see citing works
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317 · see citing works
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · see citing works
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873 · see citing works
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407 · see citing works
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M. A., Solomon, B., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,316 · see citing works
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007478 · Cited by 1,186 · see citing works
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2906 · Cited by 1,064 · see citing works
Self-citation
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Koivunen, J. P., Mermel, C. H., Zejnullahu, K., Murphy, C., Lifshits, E., Tisch, A. H., Choi, H. G., Kim, J., Chiang, D. Y., Thomas, R. K., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0168 · Cited by 992 · see citing works
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
Cui, J. J., Tran‐Dubé, M., Shen, H., Nambu, M. D., Kung, P., Pairish, M., Jia, L., Meng, J. J., Funk, L. A., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 953 · see citing works
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 915 · see citing works
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Shaw, A. T., Yeap, B. Y., Solomon, B., Riely, G. J., Gainor, J. F., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 897 · see citing works
Self-citation
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix‐Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 893 · see citing works
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893 · see citing works
Crizotinib in ALK -Rearranged Inflammatory Myofibroblastic Tumor
Butrynski, J. E., D’Adamo, D. R., Hornick, J. L., Cin, P. D., Antonescu, C. R., Jhanwar, S. C., Ladanyi, M., Capelletti, M., Rodig, S. J., Ramaiya, N. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007056 · Cited by 870 · see citing works
A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841 · see citing works
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A. C., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 823 · see citing works
Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
Iwahara, T., Fujimoto, J., Wen, D., Cupples, R. L., Bucay, N., Arakawa, T., Mori, S., Ratzkin, B. J., & Yamamoto, T. S. (1997) · Oncogene · doi:10.1038/sj.onc.1200849 · Cited by 725 · see citing works
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Takeuchi, K., Choi, Y. L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3248 · Cited by 717 · see citing works
Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population
Rodig, S. J., Mino-Kenudson, M. A., Đačić, S., Yeap, B. Y., Shaw, A. T., Barletta, J. A., Stubbs, H., Law, K., Lindeman, N. I., Mark, E. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0802 · Cited by 677 · see citing works
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 641 · see citing works
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Costa, D. B., Kobayashi, S. S., Pandya, S. S., Yeo, W.-L., Shen, Z., Tan, W., & Wilner, K. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1313 · Cited by 601 · see citing works
Retrospective Analysis
Vincze, G., Barner, J. C., Linn, W. D., Johnsrud, M. T., Shepherd, M. D., & Wilson, J. P. (2015) · doi:10.1002/9781119183617.ch8 · Cited by 600 · see citing works
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Sasaki, T., Koivunen, J. P., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C. S., Marcoux, J. P., Du, J., Okuda, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1340 · Cited by 599 · see citing works
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Katayama, R., Khan, T. M., Benes, C. H., Lifshits, E., Ebi, H., Rivera, V. M., Shakespeare, W. C., Iafrate, A. J., Engelman, J. A., & Shaw, A. T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019559108 · Cited by 546 · see citing works
ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
Morris, S. W., Naeve, C. W., Mathew, P., et al. (1997) · Oncogene · doi:10.1038/sj.onc.1201062 · Cited by 530 · see citing works
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K. E., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M. E., Sos, M. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002356 · Cited by 519 · see citing works
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study
von Bubnoff, N. C. C., Schneller, F., Peschel, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07679-1 · Cited by 466 · see citing works
EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
Inamura, K., Takeuchi, K., Togashi, Y., Nomura, K., Ninomiya, H., Okui, M., Satoh, Y., Okumura, S., Nakagawa, K., Soda, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815e8b60 · Cited by 466 · see citing works
Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors
Raut, C. P., Posner, M. A., Desai, J., Morgan, J. A., George, S., Zahrieh, D., Fletcher, C. D. �., Demetri, G. D., & Bertagnolli, M. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3439 · Cited by 448 · see citing works
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
Ou, S. I., Kwak, E. L., Siwak, C. T., Dy, J., Bergethon, K. E., Clark, J. W., Camidge, D. R., Solomon, B., Maki, R. G., Bang, Y., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821528d3 · Cited by 435 · see citing works
Self-citation
MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
Lennerz, J. K., Kwak, E. L., Ackerman, A., Michael, M., Fox, S. B., Bergethon, K. E., Lauwers, G. Y., Christensen, J. G., Wilner, K. D., Haber, D. A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4928 · Cited by 433 · see citing works
Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
McDermott, U., Iafrate, A. J., Gray, N. S., Shioda, T., Classon, M., Maheswaran, S., Zhou, W., Choi, H. G., Smith, S. L., Dowell, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6186 · Cited by 397 · see citing works
Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin
Stoica, G. E., Kuo, A. H., Aigner, A. M., Sunitha, I., Souttou, B., Malerczyk, C., Caughey, D. J., Wen, D., Karavanov, A. A., Riegel, A. T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010660200 · Cited by 382 · see citing works
Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types
Stoica, G. E., Kuo, A. H., Powers, C., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205749200 · Cited by 359 · see citing works
Fusion of the ALK Gene to the Clathrin Heavy Chain Gene, CLTC, in Inflammatory Myofibroblastic Tumor
Bridge, J. A., Kanamori, M., Ma, Z., Pickering, D. L., Hill, D. A., Lydiatt, W. M., Lui, M. Y., Colleoni, G. W. B., Antonescu, C. R., Ladanyi, M., et al. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61711-7 · Cited by 354 · see citing works
Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
Camidge, D. R., Kono, S. A., Flacco, A., Tan, A. C., Doebele, R. C., Zhou, Q. H., Crinò, L., Franklin, W. A., & Varella‐Garcia, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0851 · Cited by 341 · see citing works
Self-citation
The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
Sasaki, T., Okuda, K., Zheng, W., Butrynski, J. E., Capelletti, M., Wang, L., Gray, N. S., Wilner, K. D., Christensen, J. G., Demetri, G. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2956 · Cited by 333 · see citing works
Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
Sequist, L. V. D., Gettinger, S. N., Senzer, N. N., Martins, R. G., Janne, P. A., Lilenbaum, R., Gray, J. E., Iafrate, A. J., Katayama, R., Hafeez, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8338 · Cited by 331 · see citing works
EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
Horn, L., & Pao, W. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6661 · Cited by 317 · see citing works
ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases
Gascoyne, R. D. (2003) · Blood · doi:10.1182/blood-2003-03-0786 · Cited by 299 · see citing works
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
Zhang, X., Zhang, S., Yang, X., Yang, J., Zhou, Q. H., Yin, L., An, S., Lin, J., Chen, S., Xie, Z., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-188 · Cited by 296 · see citing works
Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor
Ma, Z., Hill, D. A., Collins, M. H., et al. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10177 · Cited by 281 · see citing works
Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer
Doebele, R. C., Lu, X. J. D., Sumey, C. J., Maxson, D. A., Weickhardt, A. J., Oton, A. B., Bunn, P. A., Barón, A. E., Franklin, W. A., Aisner, D. L., et al. (2012) · Cancer · doi:10.1002/cncr.27409 · Cited by 279 · see citing works
Self-citation
Crizotinib in Anaplastic Large-Cell Lymphoma
Gambacorti-Passerini, C. B., Messa, C., & Pogliani, E. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1013224 · Cited by 277 · see citing works
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
Camidge, D. R., Kono, S. A., Lu, X. J. D., Okuyama, S., Barón, A. E., Oton, A. B., Davies, A. M., Varella‐Garcia, M., Franklin, W. A., & Doebele, R. C. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820cf053 · Cited by 238 · see citing works
Self-citation
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
Webb, T. R., Slavish, J., George, R. E., Look, A. T., Xue, L., Jiang, Q., Cui, X., Rentrop, W. B., & Morris, S. W. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.3.331 · Cited by 232 · see citing works
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).
Kris, M. G., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Aronson, S. L., Engelman, J. A., Shyr, Y., Khuri, F. R., Rudin, C. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.cra7506 · Cited by 213 · see citing works
Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers
Lee, H., Norris, A., Weiss, J. B., et al. (2003) · Nature · doi:10.1038/nature01916 · Cited by 194 · see citing works
Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.
Spigel, D. R., Ervin, T. J., Ramlau, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7505 · Cited by 194 · see citing works
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
Murugan, A. K., & Xing, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4041 · Cited by 193 · see citing works
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Heuckmann, J. M., Hölzel, M., Sos, M. L., Heynck, S., Balke‐Want, H., Koker, M., Peifer, M., Weiss, J. M., Lovly, C. M., Grütter, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1648 · Cited by 192 · see citing works
Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
Chen, Z., Sasaki, T., Tan, X., Carretero, J., Shimamura, T., Li, D., Xu, C., Wang, Y., Adelmant, G., Capelletti, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1671 · Cited by 192 · see citing works
The role of Hsp90 in protein complex assembly
Makhnevych, T., & Houry, W. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.09.001 · Cited by 184 · see citing works
The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma.
Beau, M. M. L., Bitter, M., Larson, R. A., et al. (1989) · PubMed · Cited by 180 · see citing works
Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion
Englund, C., Lorén, C. E., Grabbe, C., et al. (2003) · Nature · doi:10.1038/nature01950 · Cited by 179 · see citing works
Characterization of the expression of the ALK receptor tyrosine kinase in mice
Vernersson, E., Khoo, N. K. S., Henriksson, M. L., Roos, G., Palmer, R. H., & Hallberg, B. (2006) · Gene Expression Patterns · doi:10.1016/j.modgep.2005.11.006 · Cited by 177 · see citing works
ATIC-ALK: A Novel Variant ALK Gene Fusion in Anaplastic Large Cell Lymphoma Resulting from the Recurrent Cryptic Chromosomal Inversion, inv(2)(p23q35)
Colleoni, G. W. B., Bridge, J. A., Garicochea, B., et al. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64945-0 · Cited by 174 · see citing works
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Costa, D. B., Nguyen, K.-S. H., Cho, B. C., Sequist, L. V., Jackman, D. M., Riely, G. J., Yeap, B. Y., Halmos, B., Kim, J. H., Jänne, P. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1455 · Cited by 171 · see citing works
Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.
Crinò, L., Kim, D. S., Riely, G. J., Janne, P. A., Blackhall, F. H., Camidge, D. R., Hirsh, V., Mok, T. S. K., Solomon, B., Park, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7514 · Cited by 171 · see citing works
Self-citation
Anterograde Jelly belly and Alk Receptor Tyrosine Kinase Signaling Mediates Retinal Axon Targeting in Drosophila
Bazigou, E., Apitz, H., Johansson, J., et al. (2007) · Cell · doi:10.1016/j.cell.2007.02.024 · Cited by 162 · see citing works
Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
Lee, J., Kim, T. M., Lee, S., Kim, D., Kim, S., Jeon, Y., Chung, D. H., Kim, W. H., Kim, Y. T., Yang, S.-C., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182208fc2 · Cited by 159 · see citing works
The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
Normant, E., Paez, G., West, K. A., et al. (2011) · Oncogene · doi:10.1038/onc.2010.625 · Cited by 146 · see citing works
Identification of anaplastic lymphoma kinase fusions in renal cancer
Sugawara, E., Togashi, Y., Kuroda, N., et al. (2012) · Cancer · doi:10.1002/cncr.27391 · Cited by 143 · see citing works
Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma
Yang, P., Kulig, K., Boland, J. M., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823c5c32 · Cited by 142 · see citing works
Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
Camidge, D. R., Bang, Y., Kwak, E. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2501 · Cited by 135 · see citing works
Self-citation
Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis Screen
Zhang, S., Wang, F., Keats, J. A., et al. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01239.x · Cited by 133 · see citing works
Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini, P., Gastaldi, T., Falini, B., & Rosolen, A. (2002) · PubMed · Cited by 131 · see citing works
Activation of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Induces Neuronal Differentiation through the Mitogen-activated Protein Kinase Pathway
Souttou, B., Carvalho, N. B.-D., Raulais, D., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007333200 · Cited by 128 · see citing works
Anaplastic Lymphoma Kinase Aberrations in Rhabdomyosarcoma: Clinical and Prognostic Implications
Gaál, J., Flucke, U. E., Roeffen, M. H. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8588 · Cited by 127 · see citing works
Crizotinib and Testing for ALK
Shaw, A. T., Solomon, B. J., & Kenudson, M. M. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0115 · Cited by 123 · see citing works
A crucial role for the Anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster
Lorén, C. E., Englund, C., Grabbe, C., et al. (2003) · EMBO Reports · doi:10.1038/sj.embor.embor897 · Cited by 122 · see citing works
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
Becker, A., Crombag, L., Heideman, D. A. M., Thunnissen, F. B., van Wijk, A. W., Postmus, P. E., & Smit, E. F. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.046 · Cited by 117 · see citing works
Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo
Lorén, C. E., Scully, A. L., Grabbe, C., Edeen, P. T., Thomas, J. B., McKeown, M., Hunter, T. R., & Palmer, R. H. (2001) · Genes to Cells · doi:10.1046/j.1365-2443.2001.00440.x · Cited by 111 · see citing works
The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
Atherly, A. J., & Camidge, D. R. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.60 · Cited by 104 · see citing works
Self-citation
Sensitive Detection of BCR-ABL1 Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy
Parker, W. T., Lawrence, R., Ho, M., Irwin, D. L., Scott, H. S., Hughes, T. P., & Branford, S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0934 · Cited by 96 · see citing works
Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer
Camidge, D. R., Theodoro, M. F., Maxson, D. A., et al. (2012) · Cancer · doi:10.1002/cncr.27411 · Cited by 93 · see citing works
Self-citation
Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
Weickhardt, A. J., Rothman, M. S., Salian‐Mehta, S., Kiseljak‐Vassiliades, K., Oton, A. B., Doebele, R. C., Wierman, M. E., & Camidge, D. R. (2012) · Cancer · doi:10.1002/cncr.27450 · Cited by 91 · see citing works
Self-citation
EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR
Wu, S., Kuo, Y.-W., Chang, Y., Shih, J., Chen, Y., Tsai, M., Yu, C., Yang, C.-H., & Yang, P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182370e30 · Cited by 90 · see citing works
Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib
Popat, S., Araújo, A., Min, T., Swansbury, J. G., Dainton, M., Wotherspoon, A. C., Lim, E. K. S., Nicholson, A. G., & O'Brien, M. E. R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822eec5e · Cited by 71 · see citing works
An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Wong, K., Koczywas, M., Goldman, J. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7500 · Cited by 62 · see citing works
Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib
Ou, S. I., Azada, M. C., Dy, J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307e06 · Cited by 56 · see citing works
Comparative analyses of overall survival in patients with anaplastic lymphoma kinase‐positive and matched wild‐type advanced nonsmall cell lung cancer
Lee, J. K., Park, H. S., Kim, D., Kulig, K., Kim, T. M., Lee, S., Jeon, Y., Chung, D. H., Heo, D. S., Kim, W., et al. (2011) · Cancer · doi:10.1002/cncr.26668 · Cited by 52 · see citing works
Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.
Tan, W., Wilner, K. D., Bang, Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2596 · Cited by 46 · see citing works
Lung cancer in 'Never-smokers': a unique entity.
Subramanian, J., & Govindan, R. (2010) · PubMed · Cited by 42 · see citing works
Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients
Al‐Batran, S., Hartmann, J. T., Heidel, F. H., et al. (2007) · Gastric Cancer · doi:10.1007/s10120-007-0425-8 · Cited by 38 · see citing works
Abstract 4403: Differential cytotoxic effects of atorvastatin in human hepatocellular carcinoma and pancreatic adenocarcinoma cells
Lai, M. B., Bhardwaj, V., Lai, J. C. K., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4403 · Cited by 38 · see citing works
Finding ALK-Positive Lung Cancer: What Are We Really Looking for?
Camidge, D. R., Camidge, D. R., Hirsch, F. R., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820cf068 · Cited by 32 · see citing works
Self-citation
Radiotherapy in the treatment of gastrointestinal stromal tumor
Knowlton, C. A., Brady, L. W., & Heintzelman, R. C. (2011) · Rare Tumors · doi:10.4081/rt.2011.e35 · Cited by 30 · see citing works
ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC).
Varella‐Garcia, M., Cho, Y., Lu, X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.10533 · Cited by 24 · see citing works
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Weickhardt, A. J., & Camidge, D. R. (2011) · Clinical Investigation · doi:10.4155/cli.11.92 · Cited by 22 · see citing works
Self-citation
Are Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer Prognostic, Predictive, or Both?
Solomon, B. J., & Shaw, A. T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823f1289 · Cited by 6 · see citing works
Abstract 4385: Effect on retinal function as a mechanism for vision disorders with crizotinib (PF-02341066)
Matsumoto, D., Liu, C., Somps, C. J., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4385 · Cited by 2 · see citing works

Flagged first, then by citations

Sorted by citations

Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · see citing works
Self-citation
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190 · see citing works
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850 · see citing works
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684 · see citing works
Self-citation
Genetic instability and recurrent MYC amplification in ALK‐translocated NSCLC: a central role of TP53 mutations
Alidousty, C., Baar, T., Martelotto, L. G., Heydt, C., Wagener, S., Fassunke, J., Duerbaum, N., Scheel, A. H., Frank, S., Holz, B., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5110 · Cited by 69 · see citing works

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers
Lucena-Araujo, A. R., Moran, J. P., VanderLaan, P. A., Dias-Santagata, D. C., Folch, E. E., Majid, A., Kent, M. S., Gangadharan, S. P., Rangachari, D., Huberman, M. S., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.006 · Cited by 19 · see citing works
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
Zdżalik-Bielecka, D., Dymek, B., Grygielewicz, P., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1589-3 · Cited by 39 · see citing works
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Zhang, S., Anjum, R., Squillace, R. M., Nadworny, S., Zhou, T., Keats, J. A., Ning, Y., Wardwell, S., Miller, D., Song, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0569 · Cited by 336 · see citing works
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non–Small-Cell Lung Cancer: Analysis and Literature Review
Lin, Y., Yu, C., Yang, J. C., & Shih, J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.005 · Cited by 35 · see citing works
Ceritinib for Treatment of ALK-Rearranged Advanced Non-Small-Cell Lung Cancer
Vansteenkiste, J. (2014) · Future Oncology · doi:10.2217/fon.14.94 · Cited by 11 · see citing works

Authors: Camidge, D. R., & Doebele, R. C.
Affiliations: University of Colorado Cancer Center (US)
Corresponding author: Camidge, D. Ross
ORCID: Camidge, D. Ross
Doebele, Robert C.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2012-04-03
Volume: 9
Issue: 5
Pages: 268-277
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2012.43
PMC: PMC4142046
OpenAlex: W2040317578
Cited by: 236
References: 98
Citations by year: 2026: 2 · 2025: 7 · 2024: 6 · 2023: 8 · 2022: 10 · 2021: 13 · 2020: 6 · 2019: 13 · 2018: 18 · 2017: 14 · 2016: 27 · 2015: 30 · 2014: 26 · 2013: 44 · 2012: 12
FWCI: 6.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (K12CA086913)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: ALK-positive non-small cell lung cancer, crizotinib, anaplastic lymphoma kinase, ALK inhibitors, drug resistance mechanisms, targeted therapy, ALK rearrangement
MeSH terms: Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents, Humans, Lung Neoplasms, Disease Management, Receptor Protein-Tyrosine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treating ALK-positive lung cancer—early successes and future challenges

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks